Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

被引：0
|
作者：
Alsina, Maria [1 ]
Fleitas-Kanonnikoff, Tania [2 ]
机构：
[1] Hosp Univ Navarra, Med Oncol Dept, Translat Med Oncol Invest Grp, Navarrabiomed IdiSNA, C-Irunlarrea 3, Pamplona 35008, Spain
[2] Hosp Clin Univ Valencia, Med Oncol Dept, INCLIVA, Valencia, Spain
来源：
MED | 2024年 / 5卷 / 09期
关键词：
CHEMOTHERAPY; PLACEBO;
D O I：
10.1016/j.medj.2024.05.016
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.(1)
引用
收藏
页码：1038 / 1040
页数：3
相关论文
共 50 条
  • [41] Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
    Mantia, Charlene
    Jegede, Opeyemi
    Regan, Meredith M.
    Atkins, Michael B.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
    Stern, Peter L.
    Dalianis, Tina
    VIRUSES-BASEL, 2021, 13 (07):
  • [43] Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review
    Gong, Hongyu
    Ong, Siew Chin
    Li, Fan
    Shen, Yan
    Weng, Zhiying
    Zhao, Keying
    Jiang, Zhengyou
    Wang, Meng
    HEALTH ECONOMICS REVIEW, 2024, 14 (01):
  • [44] Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first-line treatment for advanced non-small cell lung cancer
    Rizzo, Alessandro
    THORACIC CANCER, 2022, 13 (04) : 656 - 656
  • [45] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Jin Li
    Zhendong Chen
    Yuxian Bai
    Bo Liu
    Qingshan Li
    Jingdong Zhang
    Jun Zhou
    Ting Deng
    Fuyou Zhou
    Shegan Gao
    Shujun Yang
    Feng Ye
    Long Chen
    Wei Bai
    Xianli Yin
    Shundong Cang
    Lianke Liu
    Yueyin Pan
    Hui Luo
    Yanxia Ji
    Zhen Zhang
    Jufeng Wang
    Quanliang Yang
    Na Li
    Rong Huang
    Chenglin Qu
    Jing Ni
    Bo Wang
    Yan Xu
    Jin Hu
    Qingmei Shi
    Jason Yang
    Nature Medicine, 2024, 30 : 740 - 748
  • [46] Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
    Li, Ying
    Ji, Yanyan
    Shen, Lin
    Yin, Xudong
    Huang, Tianyu
    Deng, Bin
    Guo, Hong
    Wu, Yunjiang
    Chen, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma
    Rogers, Jane E.
    Yamashita, Kohei
    Sewastjanow-Silva, Matheus
    Rosa Vicentini, Ernesto
    Waters, Rebecca
    Ajani, Jaffer A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 565 - 571
  • [48] The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma
    Chen, Ming-Qiu
    Chen, Cheng
    Lu, Hai-Jie
    Xu, Ben-Hua
    JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1749 - 1755
  • [49] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Li, Jin
    Chen, Zhendong
    Bai, Yuxian
    Liu, Bo
    Li, Qingshan
    Zhang, Jingdong
    Zhou, Jun
    Deng, Ting
    Zhou, Fuyou
    Gao, Shegan
    Yang, Shujun
    Ye, Feng
    Chen, Long
    Bai, Wei
    Yin, Xianli
    Cang, Shundong
    Liu, Lianke
    Pan, Yueyin
    Luo, Hui
    Ji, Yanxia
    Zhang, Zhen
    Wang, Jufeng
    Yang, Quanliang
    Li, Na
    Huang, Rong
    Qu, Chenglin
    Ni, Jing
    Wang, Bo
    Xu, Yan
    Hu, Jin
    Shi, Qingmei
    Yang, Jason
    NATURE MEDICINE, 2024, 30 (03) : 740 - 748
  • [50] First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis
    Zheng, Zhiwei
    Chen, Hongcai
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (03) : 397 - 404
12345